nach oben

Erschienen in:

12.06.2020 | Main topic

Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system

verfasst von: Lars Michel, MD, Matthias Totzeck, MD, Lorenz Lehmann, MD, Daniel Finke, MD

Erschienen in: Herz | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Immune checkpoint inhibitor (ICI) therapy induces an immune response against cancer cells. Immune checkpoint inhibitor therapy has tremendously improved the prognosis for a large number of cancers, but is associated with considerable immune-related adverse events (irAEs). Cardiovascular complications from ICI therapy occur in a modest proportion of patients, but show the highest lethality rates of all ICI-related complications. While ICI-related myocarditis is the most dangerous complication, its clinical manifestation varies, e.g., asymptomatic reduction of left ventricular function, isolated increase in cardiac troponins, and arrhythmias. This review delineates current data on cardiovascular complications of ICI therapy. The effects of ICI therapy on the cardiovascular system are classified in the context of preclinical data on the biochemical and immunological function of the immune checkpoint signaling pathways in the heart and the vascular system. Incidence, suspected pathomechanisms, typical symptoms, as well as recommended diagnostics are summarized. Current therapy recommendations for ICI-related cardiotoxicity are outlined and innovative new approaches with high potential for improving outcome in ICI-related myocarditis are delineated. A better understanding of cardiovascular complications is essential for the best possible oncocardiology care of the growing number of patients undergoing ICI therapy.

Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153–167. https://doi.org/10.1038/nri.2017.108CrossRefPubMed

Buchbinder EI, Desai A (2016) CTLA‑4 and PD‑1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98–106. https://doi.org/10.1097/COC.0000000000000239CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350. https://doi.org/10.1126/science.aar4060CrossRefPubMedPubMedCentral

Sznol M, Powderly JD, Smith DC et al (2010) Safety and antitumor activity of biweekly MDX-1106 (Anti-PD‑1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 28(15_suppl):2506–2506. https://doi.org/10.1200/jco.2010.28.15_suppl.2506CrossRef

Schadendorf D, van Akkooi ACJ, Berking C et al (2018) Melanoma. Lancet 392(10151):971–984. https://doi.org/10.1016/s0140-6736(18)31559-9CrossRefPubMed

Wei SC, Levine JH, Cogdill AP et al (2017) Distinct cellular mechanisms underlie anti-CTLA‑4 and anti-PD‑1 checkpoint blockade. Cell 170(6):1120–1133.e17. https://doi.org/10.1016/j.cell.2017.07.024CrossRefPubMedPubMedCentral

Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017. https://doi.org/10.1056/NEJMoa1414428CrossRefPubMedPubMedCentral

Lyon AR, Yousaf N, Battisti NML et al (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19(9):e447–e458. https://doi.org/10.1016/s1470-2045(18)30457-1CrossRefPubMed

10.

Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824–1835. https://doi.org/10.1056/NEJMoa1709030CrossRefPubMed

11.

Tang J, Yu JX, Hubbard-Lucey VM et al (2018) Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov 17(12):854–855. https://doi.org/10.1038/nrd.2018.210CrossRefPubMed

12.

Grabie N, Lichtman AH, Padera R (2019) T cell checkpoint regulators in the heart. Cardiovasc Res 115(5):869–877. https://doi.org/10.1093/cvr/cvz025CrossRefPubMedPubMedCentral

13.

Grabie N, Gotsman I, DaCosta R et al (2007) Endothelial programmed death‑1 ligand 1 (PD-L1) regulates CD8+ T‑cell mediated injury in the heart. Circulation 116(18):2062–2071. https://doi.org/10.1161/circulationaha.107.709360CrossRefPubMed

14.

Tivol EA, Borriello F, Schweitzer AN et al (1995) Loss of CTLA‑4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA‑4. Immunity 3(5):541–547PubMed

15.

Nishimura H, Okazaki T, Tanaka Y et al (2001) Autoimmune dilated cardiomyopathy in PD‑1 receptor-deficient mice. Science 291(5502):319–322. https://doi.org/10.1126/science.291.5502.319CrossRefPubMed

16.

Okazaki T, Tanaka Y, Nishio R et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9(12):1477–1483. https://doi.org/10.1038/nm955CrossRefPubMed

17.

Kaya Z, Goser S, Buss SJ et al (2008) Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation 118(20):2063–2072. https://doi.org/10.1161/CIRCULATIONAHA.108.788711CrossRefPubMedPubMedCentral

18.

Bockstahler M, Fischer A, Goetzke CC et al (2020) Heart-specific immune responses in an animal model of autoimmunerelated myocarditis mitigated by an Immunoproteasome inhibitor and genetic ablation. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.119.043171CrossRefPubMed

19.

Wang J, Okazaki IM, Yoshida T et al (2010) PD‑1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 22(6):443–452. https://doi.org/10.1093/intimm/dxq026CrossRefPubMed

20.

Lucas JA, Menke J, Rabacal WA et al (2008) Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol 181(4):2513–2521. https://doi.org/10.4049/jimmunol.181.4.2513CrossRefPubMed

21.

Waterhouse P, Penninger JM, Timms E et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla‑4. Science 270(5238):985–988PubMed

22.

Klocke K, Sakaguchi S, Holmdahl R, Wing K (2016) Induction of autoimmune disease by deletion of CTLA‑4 in mice in adulthood. Proc Natl Acad Sci U S A 113(17):E2383–E2392. https://doi.org/10.1073/pnas.1603892113CrossRefPubMedPubMedCentral

23.

Ruppert V, Meyer T, Struwe C et al (2010) Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy. Eur J Hum Genet 18(6):694–699. https://doi.org/10.1038/ejhg.2010.3CrossRefPubMedPubMedCentral

24.

Tarrio ML, Grabie N, Bu DX et al (2012) PD‑1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188(10):4876–4884. https://doi.org/10.4049/jimmunol.1200389CrossRefPubMed

25.

Fonseca R, Salgado RM, Borges da Silva H et al (2018) Programmed cell death protein 1‑PDL1 interaction prevents heart damage in chronic trypanosoma cruzi infection. Front Immunol 9:997–997. https://doi.org/10.3389/fimmu.2018.00997CrossRefPubMedPubMedCentral

26.

Hofmann U, Frantz S (2015) Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction. Circ Res 116(2):354–367. https://doi.org/10.1161/CIRCRESAHA.116.304072CrossRefPubMed

27.

Baban B, Liu JY, Qin X et al (2015) Upregulation of programmed death‑1 and its Ligand in cardiac injury models: interaction with GADD153. PLoS ONE 10(4):e124059. https://doi.org/10.1371/journal.pone.0124059CrossRefPubMedPubMedCentral

28.

Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nNivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377(14):1345–1356. https://doi.org/10.1056/NEJMoa1709684CrossRefPubMedPubMedCentral

29.

Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148. https://doi.org/10.1016/j.ejca .2015.11.016PubMed

30.

Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721–1728. https://doi.org/10.1001/jamaoncol.2018.3923CrossRefPubMedPubMedCentral

31.

Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50. https://doi.org/10.1186/s40425-016-0152-yCrossRefPubMedPubMedCentral

32.

Johnson DB, Balko JM, Compton ML et al (2016) Fulminant mocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749–1755. https://doi.org/10.1056/NEJMoa1609214CrossRefPubMedPubMedCentral

33.

Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2018.02.037CrossRefPubMedPubMedCentral

34.

Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933. https://doi.org/10.1016/s0140-6736(18)30533-6CrossRefPubMedPubMedCentral

35.

Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037CrossRefPubMedPubMedCentral

36.

Michel L, Rassaf T, Totzeck M (2019) Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 25:100420. https://doi.org/10.1016/j.ijcha.2019.100420CrossRefPubMedPubMedCentral

37.

Palaskas N, Lopez-Mattei J, Durand JB et al (2020) Immune checkpoint inhibitor myocarditis: Pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 9(2):e13757. https://doi.org/10.1161/JAHA.119.013757CrossRefPubMedPubMedCentral

38.

Michel L, Rassaf T (2019) Cardio-oncology: need for novel structures. Eur J Med Res 24(1):1. https://doi.org/10.1186/s40001-018-0359-0CrossRefPubMedPubMedCentral

39.

Michel L, Rassaf T, Totzeck M (2018) Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 10(Suppl 35):S4282–S4295. https://doi.org/10.21037/jtd.2018.08.15CrossRefPubMedPubMedCentral

40.

Awadalla M, Mahmood SS, Groarke JD et al (2020) Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol 75(5):467–478. https://doi.org/10.1016/j.jacc.2019.11.049CrossRefPubMedPubMedCentral

41.

Awadalla M, Golden DLA, Mahmood SS et al (2019) Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer 7(1):53. https://doi.org/10.1186/s40425-019-0535-yCrossRefPubMedPubMedCentral

42.

Bonaca MP, Olenchock BA, Salem J‑E et al (2019) Myocarditis in the setting of cancer therapeutics. Circulation 140(1):80–91. https://doi.org/10.1161/CIRCULATIONAHA.118.034497CrossRefPubMedPubMedCentral

43.

Rassaf T, Totzeck M, Backs J et al (2020) Onco-Cardiology: Consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. https://doi.org/10.1007/s00392-020-01636-7CrossRefPubMedPubMedCentral

44.

Zhang L, Awadalla M, Mahmood SS et al (2020) Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa051CrossRefPubMedPubMedCentral

45.

Caforio AL, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648. https://doi.org/10.1093/eurheartj/eht210CrossRefPubMed

46.

Champion SN, Stone JR (2020) Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol 33(1):99–108. https://doi.org/10.1038/s41379-019-0363-0CrossRefPubMed

47.

Cooper LT, Baughman KL, Feldman AM et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116(19):2216–2233. https://doi.org/10.1161/CIRCULATIONAHA.107.186093CrossRefPubMed

48.

Gallegos C, Rottmann D, Nguyen VQ, Baldassarre LA (2019) Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. Eur Heart J Case Rep. https://doi.org/10.1093/ehjcr/yty149CrossRefPubMedPubMedCentral

49.

Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO.2017.77.6385CrossRefPubMed

50.

Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23(8):879–886. https://doi.org/10.1634/theoncologist.2018-0130CrossRefPubMedPubMedCentral

51.

Wang DY, Okoye GD, Neilan TG et al (2017) Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep 19(3):21. https://doi.org/10.1007/s11886-017-0835-0CrossRefPubMed

52.

Jain V, Bahia J, Mohebtash M, Barac A (2017) Cardiovascular complications associated with novel cancer immunotherapies. Curr Treat Options Cardiovasc Med 19(5):36. https://doi.org/10.1007/s11936-017-0532-8CrossRefPubMed

53.

Frigeri M, Meyer P, Banfi C et al (2018) Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol 34(1):92.e1–92.e3. https://doi.org/10.1016/j.cjca.2017.09.025CrossRef

54.

Norwood TG, Westbrook BC, Johnson DB et al (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5(1):91. https://doi.org/10.1186/s40425-017-0296-4CrossRefPubMedPubMedCentral

55.

Centanni M, Moes D, Troconiz IF et al (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58(7):835–857. https://doi.org/10.1007/s40262-019-00748-2CrossRefPubMedPubMedCentral

56.

Salem JE, Allenbach Y, Vozy A et al (2019) Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med 380(24):2377–2379. https://doi.org/10.1056/NEJMc1901677CrossRefPubMed

57.

Wang H, Tian R, Gao P et al (2020) Tocilizumab for fulminant programmed death 1 inhibitor-associated myocarditis. J Thorac Oncol 15(3):e31–e32. https://doi.org/10.1016/j.jtho.2019.09.080CrossRefPubMed

58.

Esfahani K, Buhlaiga N, Thebault P et al (2019) Alemtuzumab for immune-related myocarditis due to PD‑1 therapy. N Engl J Med 380(24):2375–2376. https://doi.org/10.1056/NEJMc1903064CrossRefPubMed

59.

Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.0726CrossRefPubMedPubMedCentral

60.

Jain V, Mohebtash M, Rodrigo ME et al (2018) Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother 41(7):332–335. https://doi.org/10.1097/cji.0000000000000239CrossRefPubMed

61.

Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975. https://doi.org/10.1002/ejhf.592CrossRefPubMed

Titel: Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system
verfasst von: Lars Michel, MD
Matthias Totzeck, MD
Lorenz Lehmann, MD
Daniel Finke, MD
Publikationsdatum: 12.06.2020
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 7/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-020-04954-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Echocardiography and biomarkers for the diagnosis of cardiotoxicity

Establishing an oncocardiology service

ARENA – Projekt Vorhofflimmern in der Rhein-Neckar-Region

Prevention and treatment of venous thromboembolism in cancer patients